amibegron amibegron amibegron (sr-58,611a) was a drug developed by sanofi-aventis (now sanofi) which acts as a selective agonist for the β3 adrenergic receptor. it is the first orally active β3 agonist developed that is capable of entering the central nervous system, and has antidepressant and anxiolytic effects. amibegronclinical dataroutes ofadministrationoralatc codenonelegal statuslegal status development terminated identifiers iupac name ethyl (amino)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy)acetate cas number121524-08-1 yhcl: 121524-09-2 ypubchem cid3035442iuphar/bps568chemspider108738 yuniipdq3me68u3hcl: n910cj679e ykeggd08851 ychemblchembl545437 ycomptox dashboard (epa)dtxsid6047361 chemical and physical dataformulac22h26clno4molar mass403.90 g·mol−13d model (jsmol)interactive image smiles ccoc(=o)coc3ccc1ccc(cc1c3)ncc(o)c2cc(cl)ccc2 inchi inchi=1s/c22h26clno4.clh/c1-2-27-22(26)14-28-20-9-7-15-6-8-19(11-17(15)12-20)24-13-21(25)16-4-3-5-18(23)10-16;/h3-5,7,9-10,12,19,21,24-25h,2,6,8,11,13-14h2,1h3;1h/t19-,21-;/m0./s1 ykey:nqizcdqcnycvas-rqbpzybgsa-n y (verify) on july 31, 2008, sanofi-aventis announced that it has decided to discontinue development of amibegron.